文献速递妇科

60岁以下MLH1甲基化子宫内膜癌作为高危体质性MLH1表突变女性携带者的「前哨」癌症

MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
PubMed 文献 · Gynecol Oncol · 2023-03-08

本研究在错配修复缺陷且MLH1甲基化的子宫内膜癌患者中筛查体质性MLH1甲基化,癌症门诊4例中3例阳性(36-59岁),人群队列中OCCPI队列24例中1例36岁阳性,Columbus-area队列68例均阴性。体质性MLH1甲基化可表现为低水平嵌合,子宫内膜癌可为首个或双首发癌症,早发性或同时/异时性肿瘤伴MLH1甲基化者需筛查。

要点

  • 癌症门诊4例MMRd且MLH1甲基化子宫内膜癌中3例检出体质性MLH1甲基化。
  • 合并队列中<50岁患者6例中1例(约17%)、<60岁45例中1例(约2%)检出。
  • 3例体质性MLH1甲基化患者中子宫内膜癌为首个或双首发癌症。

核心结论

  • 首次癌症表现时正确诊断很重要,将显著改变临床管理。
  • 早发性子宫内膜癌或同时/异时性肿瘤(任何年龄)伴MLH1甲基化者需筛查体质性MLH1甲基化。

研究设计与样本

  • 对MMRd且MLH1甲基化的子宫内膜癌患者,用焦磷酸测序和实时甲基化特异性PCR检测血中体质性MLH1甲基化。
  • 癌症门诊纳入4例<60岁患者;人群队列包括Columbus-area队列68例(所有年龄)和OCCPI队列24例(<60岁)。

主要发现

  • 癌症门诊4例中3例(诊断年龄36至59岁)检出体质性MLH1甲基化,其中2例为单/半等位基因表突变(约50%等位基因甲基化)。
  • 1例多原发肿瘤患者正常组织低水平嵌合,所有肿瘤未甲基化等位基因存在体细胞「二次打击」,证明因果关系。
  • Columbus-area队列68例均阴性;OCCPI队列24例中1例36岁患者检出低水平嵌合体质性MLH1甲基化。
  • 合并队列中<50岁患者6例中1例(约17%)、<60岁患者45例中1例(约2%)检出。
  • 3例体质性MLH1甲基化患者中子宫内膜癌为首个或双首发癌症。

临床怎么用

  • 作者认为首次癌症表现时正确诊断很重要,将显著改变临床管理。
  • 作者认为早发性子宫内膜癌或同时/异时性肿瘤(任何年龄)伴MLH1甲基化者需筛查体质性MLH1甲基化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Universal screening of endometrial carcinoma (EC) for mismatch repair deficiency (MMRd) and Lynch syndrome uses presence of MLH1 methylation to omit common sporadic cases from follow-up germline testing. However, this overlooks rare cases with high-risk constitutional MLH1 methylation (epimutation), a poorly-recognized mechanism that predisposes to Lynch-type cancers with MLH1 methylation. We aimed to determine the role and frequency of constitutional MLH1 methylation among EC cases with MMRd, MLH1-methylated tumors. METHODS: We screened blood for constitutional MLH1 methylation using pyrosequencing and real-time methylation-specific PCR in patients with MMRd, MLH1-methylated EC ascertained from (i) cancer clinics (n = 4, <60 years), and (ii) two population-based cohorts; "Columbus-area" (n = 68, all ages) and "Ohio Colorectal Cancer Prevention Initiative (OCCPI)" (n = 24, <60 years). RESULTS: Constitutional MLH1 methylation was identified in three out of four patients diagnosed between 36 and 59 years from cancer clinics. Two had mono-/hemiallelic epimutation (∼50% alleles methylated). One with multiple primaries had low-level mosaicism in normal tissues and somatic "second-hits" affecting the unmethylated allele in all tumors, demonstrating causation. In the population-based cohorts, all 68 cases from the Columbus-area cohort were negative and low-level mosaic constitutional MLH1 methylation was identified in one patient aged 36 years out of 24 from the OCCPI cohort, representing one of six (∼17%) patients <50 years and one of 45 patients (∼2%) <60 years in the combined cohorts. EC was the first/dual-first cancer in three patients with underlying constitutional MLH1 methylation. CONCLUSIONS: A correct diagnosis at first presentation of cancer is important as it will significantly alter clinical management. Screening for constitutional MLH1 methylation is warranted in patients with early-onset EC or synchronous/metachronous tumors (any age) displaying MLH1 methylation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hitchins MP, Alvarez R, Zhou L, et al. MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation. Gynecol Oncol. 2023. PMID: 36893489. doi:10.1016/j.ygyno.2023.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。